These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36869794)

  • 21. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review.
    van der Plas WY; Dulfer RR; Engelsman AF; Vogt L; de Borst MH; van Ginhoven TM; Kruijff S;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1902-1908. PubMed ID: 28402557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
    McManus C; Oh A; Lee JA; Hur C; Kuo JH
    Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
    Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
    BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
    Sohn WY; Portale AA; Salusky IB; Zhang H; Yan LL; Ertik B; Shahinfar S; Lee E; Dehmel B; Warady BA
    Pediatr Nephrol; 2019 Jan; 34(1):145-154. PubMed ID: 30141180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes.
    Mathur A; Sutton W; Ahn JB; Prescott JD; Zeiger MA; Segev DL; McAdams-DeMarco M
    Transplantation; 2021 Dec; 105(12):e366-e374. PubMed ID: 33534525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.
    Zhang Y; Lu Y; Feng S; Zhan Z; Shen H
    Ren Fail; 2019 Nov; 41(1):921-929. PubMed ID: 31573378
    [No Abstract]   [Full Text] [Related]  

  • 30. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.
    Aladrén Regidor MJ
    Clin Nephrol; 2009 Feb; 71(2):207-13. PubMed ID: 19203518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
    Tominaga Y; Matsuoka S; Uno N; Sato T
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
    Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
    Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Alvarado L; Sharma N; Lerma R; Dwivedi A; Ahmad A; Hechanova A; Payan-Schober F; Nwosu A; Alkhalili E
    World J Surg; 2022 Apr; 46(4):813-819. PubMed ID: 35022799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
    Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
    BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
    Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
    Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
    Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
    Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
    Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.